Vertex Pharmaceuticals is initiating two Phase 3 clinical trials into the safety and efficacy of a potentially new, next-generation triple combination therapy for cystic fibrosis (CF): VX-121 plus tezacaftor and VX-561 (deutivacaftor). Expected to begin later this year, the development program will compare this once-daily therapy with Vertex’s…

If I were a superhero, my Achilles’ heel would be water. Before I illustrate, I must explain how anti-rejection medications work. A healthy immune system is trained to attack foreign bodies such as viruses because they’re often harmful. When I received my double-lung transplant in June 2019 due…

Among people with cystic fibrosis (CF), antibiotic-resistant Staphylococcus aureus is sometimes transmitted among relatives, but rarely in healthcare settings, an analysis of patients at a CF center in Iowa suggested. Findings also indicate that distinct subsets of S. aureus may be associated with differences in disease progression. These results were in the…

In many ways, I feel unqualified to write for a publication about cystic fibrosis. I was lucky enough to be born only as a CF carrier, while my younger brother, Brad, drew the short straw in the Punnett square game. Besides, my day-to-day life is no longer affected…

This year’s Cystic Fibrosis Foundation (CFF) Impact Grants will support three new virtual programs that support the well-being of people of all ages living with cystic fibrosis (CF). These winning projects range from a virtual video performance with tailored songs for hospitalized children with CF, to online exercise classes for teenagers,…